"These first two projects of international scope bear witness to the entrepreneurial spirit of Quebec researchers, who are more than 3,000 strong across the province, and to their contribution to global human health research. Thanks to this innovation fund created in partnership with Pfizer, we will have the opportunity to support several other major research projects in the next few years," says Yves Joanette, President and Chief Executive Officer of the Fonds de la recherche en sant?© du Qu?©bec.

"In Quebec and across Canada, Pfizer strives to promote joint projects that encourage innovation, in association with the scientific community, governments, patients and the industry. We are proud to support this quest for excellence in genomics in Quebec, which paves the way for personalized medicine for patients with inflammatory bowel disease or metastatic colorectal cancer. This initiative in these fields where there is a genuine need will clearly contribute to determining the appropriate treatment, the right dose and the right time for a given patient. Not only will these researchers' scientific diligence speed up progress, it will also maintain Quebec's position as a leader that encourages innovation," says Paul L?©vesque, president of Pfizer Canada.

Source: FONDS DE LA RECHERCHE EN SANTE DU QUEBEC